Cargando…

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease

PURPOSE: Immune globulins for IgG supplementation have been produced for over 35 years with essentially no differentiating features regarding their specific antibody composition. Furthermore, the compositions of plasma donor pools used for IG manufacturing are not standardized. While all immune glob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasserman, Richard L., Lumry, William, Harris, James, Levy, Robyn, Stein, Mark, Forbes, Lisa, Cunningham-Rundles, Charlotte, Melamed, Isaac, Kobayashi, Ai Lan, Du, Wei, Kobayashi, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940435/ https://www.ncbi.nlm.nih.gov/pubmed/27324887 http://dx.doi.org/10.1007/s10875-016-0308-z

Ejemplares similares

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2012)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
por: Perez, Elena E., et al.
Publicado: (2021)

Prioritization of Evidence-Based Indications for Intravenous Immunoglobulin
por: Orange, Jordan S., et al.
Publicado: (2013)

The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV
por: Cullen, Lori M., et al.
Publicado: (2017)

Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses
por: Orange, Jordan S., et al.
Publicado: (2015)

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex(®) 10% Versus Gammaplex(®) 5% in Subjects with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2017)

Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome
por: Melamed, Isaac, et al.
Publicado: (2021)

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2017)

2781. Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers
por: Cai, Bing, et al.
Publicado: (2019)

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
por: Borte, Michael, et al.
Publicado: (2017)

2630. Treatment of RSV Lower Respiratory Tract Infection in Two Immunocompromised Children with Polyclonal Immunoglobulin Containing Standardized Levels of Neutralizing Anti-RSV Antibody
por: Levy, Emily Ruth, et al.
Publicado: (2019)

Immunodeficiency and Mucosal Immunity
por: Cunningham-Rundles, Charlotte
Publicado: (2005)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
por: Hagan, John B., et al.
Publicado: (2010)

Intravenous immunoglobulin for the treatment of Kawasaki disease
por: Broderick, Cathryn, et al.
Publicado: (2023)

Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study
por: Melamed, Isaac R., et al.
Publicado: (2021)

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2019)

Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy
por: Wasserman, Richard L., et al.
Publicado: (2017)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2022)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Seeking Relevant Biomarkers in Common Variable Immunodeficiency
por: Ho, Hsi-en, et al.
Publicado: (2022)

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H, et al.
Publicado: (2022)

Anti A/B Antibody Titer Rebound: Are we Making it Worse? Be Aware of Your Intravenous Immunoglobulin
por: Kher, A., et al.
Publicado: (2018)

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency
por: Kaarthigeyan, K., et al.
Publicado: (2011)

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency
por: Bhatt, Girish Chandra, et al.
Publicado: (2012)

Does Intravenous Immunoglobulin Therapy Prolong Immunodeficiency in Transient Hypogammaglobulinemia of Infancy?
por: Memmedova, Lale, et al.
Publicado: (2013)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
por: Gill, Parwinder K., et al.
Publicado: (2018)

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
por: Gupta, Sudhir, et al.
Publicado: (2023)

Interstitial Lung Disease in Common Variable Immunodeficiency
por: Lopes, Joao Pedro, et al.
Publicado: (2021)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
por: Van Der Plas, Johan L., et al.
Publicado: (2019)

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
por: Schroeder, H. W., et al.
Publicado: (2012)

Non-infectious Complications of Common Variable Immunodeficiency: Updated Clinical Spectrum, Sequelae, and Insights to Pathogenesis
por: Ho, Hsi-en, et al.
Publicado: (2020)

Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin
por: Onodera, Hiroyuki, et al.
Publicado: (2017)

Successful ABO-incompatible living donor liver transplantation using splenectomy and intravenous immunoglobulin in high isoagglutinin titer patients
por: Lee, Boram, et al.
Publicado: (2020)

Levels of soluble fibrin in severe septic patients given intravenous immunoglobulin
por: Kobayashi, T, et al.
Publicado: (2009)

Intravenous Immunoglobulin Monotherapy for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency
por: Hasegawa, Mizue, et al.
Publicado: (2017)

Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection
por: Ben-Nathan, David, et al.
Publicado: (2009)

Clinical response to therapeutic plasmapheresis and intravenous immunoglobulin in pregnancies complicated by alloimmunization despite persistently high titers: Report of two cases
por: Bahkali, Nedaa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s8v8v82mf148rq07k19f7bjtcs